Intellipharmaceutics International Inc (IPCI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Intellipharmaceutics International Inc (Intellipharmaceutics) is a pharmaceutical company that researches, develops, manufactures, and commercializes novel and generic targeted oral solid dosage pharmaceuticals. The company develops its controlled-release and targeted-release oral solid dosage drugs based on its proprietary technology, Hypermatrix, a multidimensional controlled-release drug delivery platform. Its products and product candidates are used for the treatment of various indications, including neuropathic pain, attention deficit hyperactivity disorder (ADHD), schizophrenia, bipolar disorder, major depressive disorder, hypertension, type 2 diabetes, and chronic angina. It offers a comprehensive range of services, including pre-formulation studies, design, and development through to regulatory approval. Intellipharmaceutics is headquartered in Toronto, Ontario, Canada.

Intellipharmaceutics International Inc (IPCI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 11
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 12
Equity Offering 13
Intellipharmaceutics Raises USD14.3 Million in Public Offering of Shares and Warrants 13
Intellipharmaceutics Raises USD1.8 Million in Private Placement of Shares 15
Intellipharmaceutics Raises USD3.5 Million in Private Placement of Shares and Warrants 16
Intellipharmaceutics Raises USD4 Million in Private Placement of Shares 17
Intellipharmaceutics International to Raise up to USD4 Million in Public Offering of Shares 19
Intellipharmaceutics International Raises USD5.2 Million in Public Offering of Units 20
Intellipharmaceutics International Announces Public Offering Of Shares For Up To US$17 Million 22
Intellipharmaceutics International Completes Public Offering Of Units For US$3 Million 23
Intellipharmaceutics International Completes Private Placement Of Units For US$3 Million 24
Intellipharmaceutics International Completes Public Offering Of Common Stock For US$5 Million 25
Debt Offering 27
Intellipharmaceutics Raises USD0.5 Million in Private Placement of 10% Debenture Due 2030 27
Intellipharmaceutics International Completes Private Placement Of Debentures Due 2015 For US$1.5 Million 28
Intellipharmaceutics International Inc - Key Competitors 29
Intellipharmaceutics International Inc - Key Employees 30
Intellipharmaceutics International Inc - Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Oct 15, 2018: Intellipharmaceutics announces third quarter 2018 results 32
Jul 16, 2018: Intellipharmaceutics reports second quarter 2018 results 35
Apr 16, 2018: Intellipharmaceutics Reports First Quarter 2018 Results 38
Oct 10, 2017: Intellipharmaceutics Announces Third Quarter 2017 Results 41
Jul 11, 2017: Intellipharmaceutics Announces Second Quarter 2017 Results 43
Apr 11, 2017: Intellipharmaceutics Announces First Quarter 2017 Results 45
Feb 10, 2017: Intellipharmaceutics Announces 2016 Year End Results 48
Corporate Communications 51
Nov 05, 2018: Intellipharmaceutics: Resignation of Chief Financial Officer 51
Jun 08, 2018: Intellipharmaceutics Receives Anticipated Additional Staff Determination Letter from NASDAQ 52
Apr 27, 2018: Intellipharmaceutics Files Appeal to Nasdaq Delisting Determination 53
Sep 01, 2017: Intellipharmaceutics Appoints New Chief Financial Officer 54
Aug 08, 2017: Intellipharmaceutics Announces Resignation of CFO 55
Legal and Regulatory 56
May 26, 2017: Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement 56
Product News 57
09/05/2017: Intellipharmaceutics Provides Operational Update 57
07/31/2017: Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit 59
05/08/2018: Intellipharmaceutics Announces Start of Intranasal Human Abuse Liability Studies for Oxycodone ER 60
Product Approvals 61
Feb 09, 2018: Intellipharmaceutics Meets with FDA Regarding Oxycodone ER NDA Development Program 61
Sep 25, 2017: Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista NDA 62
Jul 26, 2017: Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista (oxycodone hydrochloride extended release), an Abuse-Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain 63
Jun 30, 2017: Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain 64
Feb 02, 2017: Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain 65
Other Significant Developments 66
Jan 24, 2018: Intellipharmaceutics Provides Operational Update 66
Mar 16, 2017: Intellipharmaceutics Announces TSX Trading Symbol Change to "IPCI" 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70

List Of Tables


Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Intellipharmaceutics International Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 11
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 12
Intellipharmaceutics Raises USD14.3 Million in Public Offering of Shares and Warrants 13
Intellipharmaceutics Raises USD1.8 Million in Private Placement of Shares 15
Intellipharmaceutics Raises USD3.5 Million in Private Placement of Shares and Warrants 16
Intellipharmaceutics Raises USD4 Million in Private Placement of Shares 17
Intellipharmaceutics International to Raise up to USD4 Million in Public Offering of Shares 19
Intellipharmaceutics International Raises USD5.2 Million in Public Offering of Units 20
Intellipharmaceutics International Announces Public Offering Of Shares For Up To US$17 Million 22
Intellipharmaceutics International Completes Public Offering Of Units For US$3 Million 23
Intellipharmaceutics International Completes Private Placement Of Units For US$3 Million 24
Intellipharmaceutics International Completes Public Offering Of Common Stock For US$5 Million 25
Intellipharmaceutics Raises USD0.5 Million in Private Placement of 10% Debenture Due 2030 27
Intellipharmaceutics International Completes Private Placement Of Debentures Due 2015 For US$1.5 Million 28
Intellipharmaceutics International Inc, Key Competitors 29
Intellipharmaceutics International Inc, Key Employees 30
Intellipharmaceutics International Inc, Subsidiaries 31

List Of Figures


Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Intellipharmaceutics International Inc (IPCI) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Intellipharmaceutics International Inc (Intellipharmaceutics) is a pharmaceutical company that researches, develops, manufactures, and commercializes novel and generic targeted oral solid dosage pharmaceuticals. The company develops its controlled-release and targeted-release oral

USD 250 View Report

Intellipharmaceutics International Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Intellipharmaceutics International Inc Company Profile is a detailed strategic and analytical report on Intellipharmaceutics International Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Titan International Inc - Strategy, SWOT and Corporate Finance Report

Titan International Inc - Strategy, SWOT and Corporate Finance ReportTitan International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report

USD 175 View Report

Closure Systems International Inc - Strategy, SWOT and Corporate Finance Report

Closure Systems International Inc - Strategy, SWOT and Corporate Finance ReportClosure Systems International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information.

USD 175 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available